2016-03-09T00:00:00.000-05:00
antibody-drug conjugate therapies,0.538759
-Devise corrective measures,0.560763
millions sales,0.294064
industry intelligence solution,0.832178
discontinued pipeline projects,0.262289
Brentuximab vedotin,0.294064
area specific therapies,0.560763
Conjugate market scenario,0.432029
Antibody-Drug Conjugate products,0.302646
time pipeline,0.41079
-A snapshot,0.432029
Technology Trend,0.257103
development partner,0.395985
Seattle Genetics,0.294064
Report Highlights,0.537
transformative therapy options,0.51964
-A review,0.302646
Technology information,0.504671
investigational products,0.22754
cytotoxic drugs,-0.357652
clinical data,0.464849
pipeline strategy,0.538759
-Developing strategic initiatives,0.638682
pipeline scenario,-0.30715
Antibody-Drug Conjugate development,0.638682
key therapy areas,0.22754
pipeline,0.129528
Technology partner,0.413399
undergone collaborations,0.464849
antibody-drug conjugate,0.493362
market trends,0.210198
trastuzumab emtansine,0.294064
monoclonal antibody,0.464849
